Expertise in
15
conditions

Dr. Samuel A. Goldlust

Oncology
Saint Luke's Cancer Specialists-Plaza
4401 Wornall Rd, 
Kansas City, MO 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
15
conditions
Saint Luke's Cancer Specialists-Plaza
4401 Wornall Rd, 
Kansas City, MO 

Overview

Samuel Goldlust is an Oncologist practicing medicine in Kansas City, Missouri.

Dr. Goldlust is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Glioma, and Brain Tumor.

He is actively involved in clinical research, co-authoring 20 peer reviewed articles and participating in 13 clinical trials. Dr. Goldlust is currently accepting new patients.

Specialties

Oncology

Licenses

Psychiatry & Neurology in KS

Hospital Affiliations

Hedrick Medical Center
Saint Luke's East Hospital
Saint Luke's South Hospital
St Lukes Hospital Of Kansas City

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Saint Luke's Cancer Specialists-Plaza
4401 Wornall Rd, Kansas City, MO 64111

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Enrollment Status: Recruiting
Publish Date: September 02, 2026
Intervention Type: Drug
Study Drugs: Vismodegib, GSK2256098, Capivasertib, Abemaciclib
Study Phase: Phase 2
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Other, Drug
Study Drugs: Temozolomide, Veliparib
Study Phase: Phase 2/Phase 3
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy of IGV-001, an Autologous Cell Immunotherapy With Antisense Oligonucleotide (IMV-001) Targeting IGF-1R, in Newly Diagnosed Patients With Glioblastoma
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy of IGV-001, an Autologous Cell Immunotherapy With Antisense Oligonucleotide (IMV-001) Targeting IGF-1R, in Newly Diagnosed Patients With Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: July 09, 2026
Intervention Type: Combination product, Procedure, Drug
Study Drugs: IGV-001 Cell Immunotherapy, Temozolomide
Study Phase: Phase 2
ALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study
ALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study
Enrollment Status: Active_not_recruiting
Publish Date: June 05, 2026
Intervention Type: Drug
Study Drugs: Fulvestrant, Anastrozole
Study Phase: Phase 3
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
Enrollment Status: Completed
Publish Date: April 22, 2026
Intervention Type: Other, Biological, Procedure, Drug, Radiation, Device
Study Drugs: Ipilimumab, Nivolumab, Temozolomide
Study Phase: Phase 2/Phase 3
A Multicenter, Open-Label Study With a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy
A Multicenter, Open-Label Study With a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy
Enrollment Status: Active_not_recruiting
Publish Date: April 15, 2026
Intervention Type: Drug
Study Drugs: Berubicin, Lomustine
Study Phase: Phase 2
An Open-label Phase II Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Tirabrutinib in Patients With Primary Central Nervous System Lymphoma (PCNSL)
An Open-label Phase II Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Tirabrutinib in Patients With Primary Central Nervous System Lymphoma (PCNSL)
Enrollment Status: Active_not_recruiting
Publish Date: March 30, 2026
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone in Patients With Previously Treated, Unresectable Myxoid Liposarcoma
A Phase II Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone in Patients With Previously Treated, Unresectable Myxoid Liposarcoma
Enrollment Status: Completed
Publish Date: January 27, 2025
Intervention Type: Drug
Study Drug: Efatutazone
Study Phase: Phase 2
Pilot Study of Concomitant NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma
Pilot Study of Concomitant NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma
Enrollment Status: Completed
Publish Date: November 18, 2024
Intervention Type: Device, Drug, Radiation
Study Drug: Temozolomide
Study Phase: Phase 1
View 9 Less Clinical Trials

20 Total Publications

Dual Immune Check Point Blockade in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial.
Dual Immune Check Point Blockade in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 08, 2025
Similar Doctors
Expertise in
22
conditions
Expertise in
22
conditions
Referral may be required

Medical Pavilion

2000 Olathe Boulevard, 
Kansas City, KS 
 (1.1 miles away)
913-588-1227
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jeffrey Holzbeierlein is an Oncologist practicing medicine in Kansas City, Kansas. Dr. Holzbeierlein is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Muscle Invasive Bladder Cancer, Nephrectomy, and Reconstructive Urology Surgery. Dr. Holzbeierlein is board certified in American Board Of Urology, Urology - 2004. Dr. Holzbeierlein is currently accepting new patients.

Expertise in
20
conditions
Expertise in
20
conditions
Referral may be required

The University Of Kansas Hospital

4000 Cambridge Street, 
Kansas City, KS 
 (1.1 miles away)
913-588-1227
Languages Spoken:
English, Korean
See accepted insurances
Accepting New Patients
Offers Telehealth

Eugene Lee is an Oncologist practicing medicine in Kansas City, Kansas. Dr. Lee is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Muscle Invasive Bladder Cancer, Nephrectomy, and Reconstructive Urology Surgery. Dr. Lee is board certified in American Board Of Urology, Urology - 2015. Dr. Lee is currently accepting new patients.

Expertise in
14
conditions
Expertise in
14
conditions
Referral may be required

Clinical Research Center

4350 Shawnee Mission Parkway, 
Fairway, KS 
 (2.9 miles away)
913-588-1227
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Tara Lin is an Oncologist practicing medicine in Fairway, Kansas. Dr. Lin is highly rated in 14 conditions, according to our data. Her clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Acute Myeloblastic Leukemia without Maturation, Bone Marrow Aspiration, and Colonoscopy. Dr. Lin is board certified in American Board Of Internal Medicine, Medical Oncology - 2005. Dr. Lin is currently accepting new patients.

Frequently Asked Questions about Dr. Samuel A. Goldlust

How do I make an appointment with Dr. Samuel A. Goldlust?

You can book an appointment with Dr. Samuel A. Goldlust by calling their office at 816-932-3300. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Samuel A. Goldlust a top-rated expert for Glioblastoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Samuel A. Goldlust is classified as an Elite expert for Glioblastoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Samuel A. Goldlust specialize in?

While Dr. Samuel A. Goldlust is a Oncology, they have specific expertise in Glioblastoma, Astrocytoma, and Glioma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Samuel A. Goldlust participate in research or clinical trials?

Yes. Dr. Samuel A. Goldlust has published 20 articles and abstracts on conditions like Glioblastoma. You can view a list of Dr. Samuel A. Goldlust's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Samuel A. Goldlust accept my insurance?

Dr. Samuel A. Goldlust accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 816-932-3300 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Goldlust's expertise for a condition
ConditionClose
View All 10 Distinguished Conditions
View All 18 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile